Company: MDXG
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001376339-25-000048
Chunk: 38

Company: MIMEDX GROUP, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 38
---
, The New York Times featured an article on placental allografts that included the recovery journeys of two patients who received MIMEDX products for serious wounds. The article showcased the benefits of placental allografts for a variety of wound care and surgical procedures and brought attention to the largely unknown opportunity for a mother to donate her nutrient rich placenta after a healthy C-section delivery.

#### Shareholder Engagement
We regularly engage with current and prospective shareholders to discuss our business, obtain feedback and answer questions. Topics covered in these discussions often include the Company’s executive compensation practices, leadership transitions, financial results, strategy, outlook, governance and sustainability practices. We believe regular and transparent dialogue with our investors is beneficial for all parties.

At our 2024 annual meeting of shareholders (“2024 Annual Meeting”), our shareholders approved, by a non-binding advisory vote, the compensation of our named executive officers, or NEOs. This ballot item, known as a “say-on-pay” proposal, passed with 74% of the votes cast. The voting results for this item were impacted by a recommendation from one of the major proxy advisory firms to vote against the proposal, due principally to the initial stock awards contained in the compensation package associated with the hiring of our current CEO in January 2023.

Following the 2024 Annual Meeting, we have held regular discussions with numerous shareholders, who in total represent ownership of more than 60% of our outstanding shares as of the record date. Members of our Board have participated in meetings with shareholders representing roughly one-third of outstanding shares as of the record date.

During these conversations, we have discussed the design of our executive compensation plans, which are aligned with Company performance metrics that are of highest interest to most of our shareholders, including revenue growth, profitability and cash flow generation metrics, as well as share price performance. As a result of the feedback we obtained in our discussions with shareholders, we have continued to prioritize compensation practices tied directly to these performance metrics.

Additionally, and consistent with the feedback received in prior years, the shareholders with whom we spoke generally expressed broad support for our governance practices. Shareholders also expressed support and positive feedback for the actions taken by the

<div align='center'>20</div>

Board, CEO and management team to achieve solid financial performance, while continuing to invest in product development, and serve as a leading voice in the industry for both reimbursement and regulatory reform. Furthermore, our recently expanded sustainability disclosures, including Scope 1 and 2 GHG emissions, have been positively received by